Deals this week: Danaher Corporation, Qingdao Huaren Pharmaceutical, Sinclair Pharma

Danaher Corporation has announced two public offerings of senior notes to raise €850m ($951.5m) in total through its subsidiary, DH Europe Finance SA.

Free Report

What is driving M&A activity in the MedTech space?

The COVID-19 pandemic has left an indelible mark on the MedTech landscape. Changes in how healthcare is delivered, and new treatment modalities, are creating opportunities and challenges for both new and traditional players. As companies sought out opportunities during the pandemic-driven downturn, the number and value of mergers and acquisition deals in the MedTech space increased. Companies worked to reposition themselves in the newly aligned healthcare world, but with further economic turmoil expected: will these trends be repeated? And what tech areas should firms be looking to expand their capabilities into? GlobalData’s report, “Themes driving M&A activity in the Medical Devices Sector, Q1 2022,” draws upon GlobalData’s extensive MedTech deals databases, highlighting major trends and hot themes in M&A activity. This report will assist you in:

Understanding value and volume trends in M&A from Q1 2018 to Q1 2022
Understanding regional trends in M&A activity
Understanding which medical device sectors are leading M&A activity, and which are lagging
Understanding the leading tech trends in Q1 2022 M&A activity
Knowing the key deals that occurred during Q1 2022

Download the full report to understand what to expect and how to align your business for success.

By GlobalData

By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Due on 30 June 2022 and 30 June 2027, the notes carry a coupon rate of 1.2%.

The US-based science and technology company plans to use the funds to repay short-term indebtedness and for general corporate purposes.

“The deal will help Sinclair Pharma expand its product portfolio.”

Chinese company Qingdao Huaren Pharmaceutical Co Ltd has announced a rights offering of common stock to raise CNY703m ($103.24m).

UK-based Sinclair Pharma plc (formerly Sinclair IS Pharma plc) plans to purchase the worldwide rights for US company Refine LLC’s patented Refine Support System for $11.3m.

The deal will help Sinclair Pharma expand its product portfolio.

Free Report

What is driving M&A activity in the MedTech space?

Understanding value and volume trends in M&A from Q1 2018 to Q1 2022
Understanding regional trends in M&A activity
Understanding which medical device sectors are leading M&A activity, and which are lagging
Understanding the leading tech trends in Q1 2022 M&A activity
Knowing the key deals that occurred during Q1 2022

Download the full report to understand what to expect and how to align your business for success.

By GlobalData

Free Report

What is driving M&A activity in the MedTech space?

Recommended Reports

Partnerships, Licensing, Investments and M&A Deals and Trends for December 2016 in Pharmaceut...

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – March 2011

Free Report

What is driving M&A activity in the MedTech space?

Partnerships, Licensing, Investments and M&A Deals and Trends for December 2016 in Pharmaceut...

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – March 2011